Skip to content

Study · Randomized controlled trial · 1992

4 results

Effect of a single dose of des-glycinamide-[Arg8]vasopressin or oxytocin on cognitive processes in young healthy subjects.

Bruins J, Hijman R, Van Ree JM

Peptides1 May 1992Cited by 50 (Europe PMC)

PMID1523161 (opens in a new tab)DOI10.1016/0196-9781(92)90075-e (opens in a new tab)PepBankPUB-01523161
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In young healthy men, a single intranasal dose of oxytocin (20 IU) showed a trend to attenuate initial storage and rate of storage in verbal memory.

    In plain wordsIn healthy young men, one nasal dose of oxytocin showed a trend toward weaker early storage of verbal memory than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseInitial storage and rate of storage in verbal memory
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    A trend was present for DGAVP and OXT to affect learning, i.e., storage processes of verbal memory in an opposite way; DGAVP improved, while OXT attenuated initial storage and the rate of storage.
    1 context sentence
    Summary · context
    A single dose of des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal) or oxytocin (OXT, 20 IU intranasal) was given to female and male volunteers, respectively, in a placebo-controlled double-blind trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In young healthy men, a single intranasal dose of oxytocin (20 IU) had no treatment effect on visual memory.

    In plain wordsIn healthy young men, one nasal dose of oxytocin did not change visual memory compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeVisual memory
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    No treatment effects on visual memory and vigilance were found.
    1 context sentence
    Summary · context
    A single dose of des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal) or oxytocin (OXT, 20 IU intranasal) was given to female and male volunteers, respectively, in a placebo-controlled double-blind trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In young healthy men, a single intranasal dose of oxytocin (20 IU) had no treatment effect on vigilance.

    In plain wordsIn healthy young men, one nasal dose of oxytocin did not change vigilance compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeVigilance
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    20 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    No treatment effects on visual memory and vigilance were found.
    1 context sentence
    Summary · context
    A single dose of des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal) or oxytocin (OXT, 20 IU intranasal) was given to female and male volunteers, respectively, in a placebo-controlled double-blind trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In young healthy men, vigor was reduced immediately after a single intranasal dose of oxytocin (20 IU).

    In plain wordsIn healthy young men, feelings of vigor were lower right after one nasal dose of oxytocin than after placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseVigor mood score
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    20 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Of the mood measures, vigor was reduced immediately after treatment with OXT.
    1 context sentence
    Summary · context
    A single dose of des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal) or oxytocin (OXT, 20 IU intranasal) was given to female and male volunteers, respectively, in a placebo-controlled double-blind trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.